TargTex
Portugal - Torres VedrasBiotechnology
Focus: TargTex is a Portuguese biotechnology company founded in 2019, focusing on small molecule hydrogel therapeutics for glioblastoma multiforme, a rare and aggressive brain cancer. The company is publicly listed but operates at a modest scale with a highly specialized oncology focus.
Profile data last refreshed 18h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About TargTex
AI assessmentNot HiringNo open roles listed right now. Follow TargTex to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from TargTex's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2019
Help build intelligence for TargTex
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.